Long Day's Journey into Night
By Eugene O'Neill
National Institutes of Health Location Panel Members:
Introduction by: David K. Mineta
David K. Mineta was confirmed unanimously by the United States Senate on June 22, 2010 to be the Deputy Director of Demand Reduction for the Office of National Drug Control Policy. In this position, Mr. Mineta oversees ONDCP Office of Demand Reduction which focuses on promoting drug prevention and drug treatment programs, as well as the agency's newly created focus on programs for individuals in recovery from addiction.
Mr. Mineta's focus of drug prevention and treatment services has been longstanding. Since 1996, Mr. Mineta has worked with Asian American Recovery Services (AARS) throughout the San Francisco Bay Area. He started as a manager of a youth prevention program, but rose quickly to associate director and, since 2007, deputy director. As deputy director, he oversaw all agency grant writing and institutional technology departments, and assisted in strategic planning, community consortiums, and other necessary functions. Before joining AARS, Mr. Mineta was a counselor in the San Jose Unified School District and later in Santa Clara's Alcohol and Drug Department.
From November of 2000 through July 2010, Mr. Mineta served as a trustee with the Jefferson Union High School District in Daly City. In May 2009, he was appointed to the Center for Substance Abuse Prevention National Advisory Council. Mr. Mineta served as a member of the American Public Health Association and Community Anti-Drug Coalitions of America before taking office at ONDCP.
Mr. Mineta studied Political Science at the University of California, Berkeley and earned his Masters of Social Work from California State University, San Jose in 1990.
Paul Christo, M.D.
Dr. Paul Christo is one of America's leading experts on relieving acute and chronic pain. For 8 years, he directed the Multidisciplinary Pain Fellowship Training Program and for 5 years the Blaustein Pain Treatment Center at The Johns Hopkins Hospital. He is a board certified, Harvard-trained anesthesiologist and Hopkins-trained pain medicine specialist. He lectures nationally and internationally, serves on journal editorial boards, teaches, co-edited 3 textbooks on pain, and has published over 60 articles and book chapters on many topics related to pain treatment, including opioids and addiction.
He hosts Aches and Gains, the first talk show on pain and pain relief that airs weekly on WBAL Radio, 1090 AM, and serves as the pain expert for the live Web Chat series on Pain Management, hosted by the Tribune newspapers and Baltimore Sun.
Nora D. Volkow, M.D.
Nora D. Volkow, M.D., became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health in May 2003. NIDA supports most of the world's research on the health aspects of drug abuse and addiction.
Dr. Volkow's work has been instrumental in demonstrating that drug addiction is a disease of the human brain. As a research psychiatrist and scientist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic effects of drugs and their addictive properties. Her studies have documented changes in the dopamine system affecting the actions of frontal brain regions involved with motivation, drive, and pleasure and the decline of brain dopamine function with age. She has also made important contributions to the neurobiology of obesity, ADHD, and the behavioral changes that occur with aging.
Dr. Volkow was born in Mexico, attended the Modern American School, and earned her medical degree from the National University of Mexico in Mexico City, where she received the Premio Robins award for best medical student of her generation. Her psychiatric residency was at New York University, where she earned the Laughlin Fellowship Award as one of the 10 Outstanding Psychiatric Residents in the USA.
Dr. Volkow spent most of her professional career at the Department of Energy's Brookhaven National Laboratory (BNL) in Upton, New York, where she held several leadership positions including Director of Nuclear Medicine, Chairman of the Medical Department, and Associate Director for Life Sciences. In addition, Dr. Volkow was a professor in the Department of Psychiatry and Associate Dean of the Medical School at the State University of New York (SUNY)-Stony Brook.
Dr. Volkow has published more than 440 peer-reviewed articles and more than 75 book chapters and nonpeer reviewed manuscripts, and has also edited three books on the use of neuroimaging in studying mental and addictive disorders.
During her professional career, Dr. Volkow has been the recipient of multiple awards, including her selection for membership in the Institute of Medicine in the National Academy of Sciences and the International Prize from the French Institute of Health and Medical Research for her pioneering work in brain imaging and addiction science. She was recently named one of Time Magazine's "Top 100 People Who Shape our World" and was included as one of the 20 people to watch by Newsweek magazine in its "Who's Next in 2007" feature. She was also included in Washingtonian Magazine's 2009 list of the "100 Most Powerful Women" and named "Innovator of the Year" by U.S. News & World Report in 2000.
American Psychological Association Location Panel Members:
Chair: David Shurtleff, Ph.D.
Dr. David Shurtleff serves as the Acting Deputy Director of the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). In this capacity, Dr. Shurtleff is responsible for providing leadership in the development, implementation, and management of NIDA's research portfolio and strategic priorities and assists the Director of NIDA to support and conduct research to improve prevention and treatment of drug use, abuse and addiction.
Prior to his current appointment, Dr. Shurtleff served as the Director of the Division of Basic Neuroscience and Behavioral Research (DBNBR). In this role, he oversaw the scientific direction of the Division to primarily support basic biomedical and behavioral science research that relates to the public health problem of drug abuse and addiction. Dr. Shurtleff also served as the DBNBR Deputy Director and worked in the Behavioral Sciences Research Branch to actively support extramural research in the basic behavioral sciences, including research in the cognitive sciences, behavioral economics, decision theory, and human and animal models of impulsivity, risk taking and other aspects of drug addiction.
Before coming to NIDA, Dr. Shurtleff was a Research Psychologist at the Naval Medical Research Institute in Bethesda and conducted basic behavioral, electrophysiological, cognitive, and field research on a variety of issues related to cognitive performance, environmental stress, and peripheral neuropathy. He also served as a Research Fellow at the Walter Reed Army Institute of Research, in the Department of Medical Neurosciences.
In 2007, Dr. Shurtleff received the NIH Director's Award for outstanding contributions to the development and advancement of diverse programs in basic neuroscience and behavioral research. He is also a Fellow of the American Psychological Association's Division 28, Psychopharmacology and Substance Abuse, and Division 6, Behavioral Neuroscience and Comparative Psychology.
Kathleen Carroll, Ph.D.
Kathleen Carroll, Ph.D., graduated summa cum laude from Duke University, received her doctorate in Clinical Psychology from the University of Minnesota, and completed her predoctoral training at Yale University's Division of Substance Abuse, where she has spent her career. She is a Professor of Psychiatry at the Yale University School of Medicine, and Principal Investigator of the Center for Psychotherapy Development at Yale, NIDA's only Center focusing solely on the behavioral therapies, their mechanisms of action, and their interactions with other therapies. She is also Principal Investigator of the New England Consortium of the NIDA Clinical Trials Network.
An ISI HighlyCited researcher, and the author of over 260 journal articles, chapters and books, Dr. Carroll's research and clinical interests lie in the area of developing, specifying and evaluating evidence based treatments for substance use disorders, alone and in combination with medications. Her major accomplishments include (1) include establishing the efficacy and delayed emergence of effects of CBT, (2) efficacy of disulfiram for cocaine dependence, (3) articulating the basis for behavioral platforms for pharmacotherapy trials, (4) with Drs Lisa Onken and Bruce Rounsaville, development of the Stage Model of Psychotherapy Development, and (5) efficacy of computer-assisted training in CBT for the addictions. Dr. Carroll is the Past President of Division 50 (Addictions) of the American Psychological Association, and has received both K05 (Senior Scientist) and MERIT awards from NIDA. She received the Distinguished Scientific Contributions to Education and Training Award from Division 50 of the American Psychological Association.
Dr. Carroll serves on numerous editorial boards, advisory boards, scientific review panels, and currently serves on the Institute of Medicine's Committee on Readjustment Needs of Military Personnel, Veterans and their Families as well as on the International Scientific Committee for Annales Medico-Psychologiques (France).
Carlo C. DiClemente, Ph.D.
Carlo DiClemente received his MA in Psychology at the New School for Social Research and his Doctorate in Psychology at the University of Rhode Island. For the past 30 years he has conducted funded research in health and addictive behaviors. He has directed an outpatient alcoholism treatment program and served as a consultant to private and public treatment and prevention programs.
Dr. DiClemente is the co-developer of the Transtheoretical Model of behavior change and the author of numerous scientific articles and book chapters on motivation and behavior change and the application of this model to a variety of health and addictive behaviors. Dr. DiClemente has co-authored a self-help book based on this model of change, Changing for Good and several professional books, The Transtheoretical Model, Substance Abuse Treatment and the Stages of Change, and Group Treatment for Substance Abuse: A Stages of Change Therapy Manual. His most recent book, Addiction and Change: How Addictions Develop and Addicted People Recover was published by Guilford Press and released in paperback in 2006.
For his work in the addictions he was given the Innovators Combating Substance Abuse award by the Robert Wood Johnson Foundation and the John P. McGovern Award from the American Society on Addiction Medicine (ASAM). He has served as president of the APA Division on Addictions (50) and is a Fellow of the American Psychological Association and the Association for Psychological Science. He has received awards for his Distinguished Contribution to Scientific Psychology by the Maryland Psychological Association and the American Psychological Association' Division on Addictions.
In 2007 he was named the first Lipitz Professor of Arts, Humanities, and Social Sciences at UMBC and in 2011 he was named the UMBC Presidential Research Professor.